Digital Alchemy: The Rise of Machine and Deep Learning in Small-Molecule Drug Discovery
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26146807 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Abdul Manan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea. Hauptthemen laut MEDLINE: Drug Discovery, Deep Learning, Small Molecule Libraries, Machine Learning. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT), National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT).
Abstract (Originalsprache)
This review provides a comprehensive analysis of the transformative impact of artificial intelligence (AI) and machine learning (ML) on modern drug design, specifically focusing on how these advanced computational techniques address the inherent limitations of traditional small-molecule drug design methodologies. It begins by outlining the historical challenges of the drug discovery pipeline, including protracted timelines, exorbitant costs, and high clinical failure rates. Subsequently, it examines the core principles of structure-based virtual screening (SBVS) and ligand-based virtual screening (LBVS), establishing the critical bottlenecks that have historically impeded efficient drug development. The central sections elucidate how cutting-edge ML and deep learning (DL) paradigms, such as generative models and reinforcement learning, are revolutionizing chemical space exploration, enhancing binding affinity prediction, improving protein flexibility modeling, and automating critical design tasks. Illustrative real-world case studies demonstrating quantifiable accelerations in discovery timelines and improved success probabilities are presented. Finally, the review critically examines prevailing challenges, including data quality, model interpretability, ethical considerations, and evolving regulatory landscapes, while offering forward-looking critical perspectives on the future trajectory of AI-driven pharmaceutical innovation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Science and Technology, Ajou University, Suwon 16499, Republic of Korea.
- RexSoft Inc., 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea.
- Department of Herbal Pharmacology, College of Korean Medicine, Gachon University, 1342 Seongnamdae-ro, Sujeong-gu, Seongnam-si 13120, Republic of Korea.
ORCID-Profile: Abdul Manan, Sidra Ilyas, Donghun Lee
Förderung
- National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)
- National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT)
Zitieren
APA
Manan, A., Baek, E., Ilyas, S., & Lee, D. (2025). Digital Alchemy: The Rise of Machine and Deep Learning in Small-Molecule Drug Discovery. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146807
Vancouver
Manan A, Baek E, Ilyas S, Lee D. Digital Alchemy: The Rise of Machine and Deep Learning in Small-Molecule Drug Discovery. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146807
BibTeX
@article{Manan2025,
author = {Manan, Abdul and Baek, Eunhye and Ilyas, Sidra and Lee, Donghun},
title = {Digital Alchemy: The Rise of Machine and Deep Learning in Small-Molecule Drug Discovery},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26146807}
}
EUVIMED